Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOBER II: Oral Semaglutide on Bone Turnover in Type 2 Diabetes
NCT06050577Phase 2Active, not recruiting
- Sponsor
- University Hospital Odense
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of semaglutide, sponsored by University Hospital Odense. Started Jun 2024; status: active, not recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT06050577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050577.